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Background: Estrogen therapy has positively impact the treatment of several cancers, such as prostate, lung and
breast cancers. Moreover, several groups have reported the importance of estrogen induced gene regulation in
esophageal cancer (EC). This suggests that there could be a potential for estrogen therapy for EC. The efficient
design of estrogen therapies requires as complete as possible list of genes responsive to estrogen. Our study
develops a systems biology methodology using esophageal squamous cell carcinoma (ESCC) as a model to identify
estrogen responsive genes. These genes, on the other hand, could be affected by estrogen therapy in ESCC.
Results: Based on different sources of information we identified 418 genes implicated in ESCC. Putative estrogen
responsive elements (EREs) mapped to the promoter region of the ESCC genes were used to initially identify
candidate estrogen responsive genes. EREs mapped to the promoter sequence of 30.62% (128/418) of ESCC genes
of which 43.75% (56/128) are known to be estrogen responsive, while 56.25% (72/128) are new candidate estrogen
responsive genes. EREs did not map to 290 ESCC genes. Of these 290 genes, 50.34% (146/290) are known to be
estrogen responsive. By analyzing transcription factor binding sites (TFBSs) in the promoters of the 202 (56+146)
known estrogen responsive ESCC genes under study, we found that their regulatory potential may be characterized
by 44 significantly over-represented co-localized TFBSs (cTFBSs). We were able to map these cTFBSs to promoters of
32 of the 72 new candidate estrogen responsive ESCC genes, thereby increasing confidence that these 32 ESCC
genes are responsive to estrogen since their promoters contain both: a/mapped EREs, and b/at least four cTFBSs
characteristic of ESCC genes that are responsive to estrogen. Recent publications confirm that 47% (15/32) of these
32 predicted genes are indeed responsive to estrogen.
Conclusion: To the best of our knowledge our study is the first to use a cancer disease model as the framework to
identify hormone responsive genes. Although we used ESCC as the disease model and estrogen as the hormone,
the methodology can be extended analogously to other diseases as the model and other hormones. We believe
that our results provide useful information for those interested in genes responsive to hormones and in the design
of hormone-based therapies.Background
Esophageal cancer (EC) comprises of heterogeneous
groups of tumors that differ in pathogenesis and etio-
logical and pathological features. EC ranks among the
ten most frequent cancers worldwide with regionally
dependent incidence rates and histological subtypes
[1,2]. Statistics indicate that EC mortality rates are very
similar to incidence rates due to the relatively late stage* Correspondence: vladimir.bajic@kaust.edu.sa
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reproduction in any medium, provided the orof diagnosis, the poor efficacy of treatment [2], and the
poor prognosis of EC result in a five year survival rate of
5-20% [3]. The most recurrent histological subtype is
esophageal squamous cell carcinoma (ESCC), followed
by adenocarcinoma (ADC) [4]. ESCC has a worse prog-
nosis than ADC due to the primary ESCC tumor being
in contact with the tracheobronchial tree in 75% of
cases, while ADC is found below the tracheal bifurcation
in 94% of cases [5].
The striking 3-4:1 male predominance of ESCC was
previously ascribed to the different patterns of smokingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 ESCC genes categorized based on ERE predictions
and experimental evidence of estrogen responsiveness
Category ERE predictions Experimental evidence No. of genes
1 yes yes 56
2 yes no 72
3 no yes 146
4 no no 144
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recently Bodelon et al. reported that current users of es-
trogen and progestin therapy show reduced risk of ESCC
[6]. Previous research supports this finding as several
groups have reported estrogen induced gene regulation
in esophageal squamous cell carcinoma (ESCC) and
Barrett’s esophageal adenocarcinoma (BEAC) [7-12].
Moreover, Wang et al. specifically demonstrated that
serum level of estradiol of ESCC patients from the high
risk areas were significantly lower compared to healthy
controls from both high and low risk areas and suggested
the use of estrogen analogues as promising targets for
the prevention and treatment of ESCC [13]. Additionally,
published scientific data shows that estrogen induces an
inhibitory effect on esophageal carcinoma by activating
the estrogen receptor (ER) [7-9]. The activated ER func-
tions as a transcription factor that binds to a specific
TFBS known as the estrogen response element (ERE)
[14,15]. There are two ER subtypes, ERα and ERβ, that
are encoded on human chromosomes 6q25.1 [16] and
chromosome 14q22-24 [17], respectively. Both ERα and
ERβ bind to the same EREs, but ERα does so with an ap-
proximately twofold higher affinity [18]. Additionally,
ERβ is known to bind to ERα suppressing ERα function
[19,20]. The inverse biological effect associated with the
two ER subtypes has been confirmed to exist in ESCC
[7]. This collation of research findings suggests that the
estrogen based therapies which have improved survival
rates of cancer types such as: prostate cancer [21], lung
cancer [22], brain and spinal cord tumors [23], and breast
cancer [24], may also improve the outcome of ESCC.
Our current study aims at identifying estrogen respon-
sive genes by using ESCC as a model. Potentially, such
genes could be affected by estrogen. We propose a
methodology that provides insight into the underlying
regulation of estrogen responsive ESCC genes. We mapped
EREs to the promoters of 418 ESCC genes using the
Dragon ERE Finder version 6.0 (http://apps.sanbi.ac.za/ere/
index.php) [25]. The 418 ESCC genes were divided into
two groups: 1) genes whose promoters contain pre-
dicted EREs, and 2) genes lacking predicted EREs. These
two gene groups were further divided into those known
to be experimentally confirmed as estrogen responsive
and those that are not. To accomplish this the 418
ESCC genes were cross checked against two databases
housing estrogen responsive genes, namely KBERG [26]
and ERtargetDB [27] databases. At the time of analysis
the KBERG database contained 1516 experimentally
confirmed estrogen-responsive genes. The ERTargetDB
database contained: (a) 40 genes with 48 experimentally
verified ERE direct binding sites and 11 experimentally
verified ERE tethering sites; (b) 42 genes identified via
ChIP-on-chip assay for estrogen binding and (c) 355
genes from gene expression microarrays, all of whichwere included in this study. However, this study excludes
the 2659 computationally predicted estrogen responsive
genes included the ERTargetDB, database. Thus this study
defines estrogen responsive genes as genes that can be
modulated by an external estrogen source.
We classified the 418 ESCC genes into the following
four categories (Table 1):
C1/ESCC genes with predicted EREs in their promoters
and known as estrogen responsive,
C2/ESCC genes with predicted EREs in their promoters
but not known as estrogen responsive,
C3/ESCC genes having no predicted EREs in their
promoters, but known as estrogen responsive,
C4/ESCC genes having no predicted EREs in their
promoters and not known as estrogen responsive.
We used these categories to develop a methodology
for the identification of co-localized TFBSs (cTFBSs) that
characterize the promoters of the known estrogen re-
sponsive gene sets (class (C1 and C3)) as opposed to the
background set (class C4). These significant cTFBSs
were mapped to the promoter sequences of the candi-
date estrogen responsive ESCC genes in class C2. The
genes in class C2 whose promoters contained such
cTFBSs were singled out as novel putative estrogen re-
sponsive genes in ESCC (class C2A).
To the best of our knowledge our study provided the
first computational large-scale analysis of the transcrip-
tion potential of estrogen responsive ESCC genes and
suggests important regulatory potential of these genes.
Although we used ESCC as a model, the developed sys-
tem biology based methodology has a potential to identify
hormone responsive genes using other hormone-affected
diseases, and provides a framework for identifying hor-
mone responsive genes based on complex diseases.
Results
The prediction and identification of putative estrogen
responsive genes in ESCC
A sequential two-step process was used to predict and
verify estrogen responsive genes in ESCC:
(a) EREs were mapped to the promoters of ESCC
genes, and
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were classified as being estrogen responsive or not.
The 418 ESCC genes were extracted from the Dragon
Database of Genes Implicated in Esophageal Cancer
(DDEC) [28]. The 1645 putative promoters of these
ESCC genes (1200 bp upstream and 200 bp downstream
from the transcription start site) were extracted from
the Fantom3 CAGE tag data [29] and analyzed for the
presence of EREs via the Dragon ERE Finder version 6.0
(http://apps.sanbi.ac.za/ere/index.php) [25]. EREs were
mapped to 242 promoter sequences that correspond to
128 ESCC genes. 290 ESCC genes had no EREs mapped
to the promoter sequences. Lists of genes that have been
experimentally validated to be responsive to estrogen as
indicated in the KBERG [26] and ERTargetDB [27] data-
bases were used to confirm which ESCC genes are re-
sponsive to estrogen (Additional file 1). Of the 128
genes with predicted EREs, 43.75% (56/128) are known
to be estrogen responsive (class C1), while 56.25% (72/
128) were new candidate estrogen responsive genes
(class C2). EREs did not map to 290 ESCC genes of
which 50.34% (146/290) are known to be estrogen re-
sponsive (class C3) (Table 1).
TFBS analysis of estrogen responsive genes in ESCC
TFBS analysis entailed the following three steps: (a)
mapping the TFBSs matrix models to the promoters of
all ESCC genes, (b) determining the cTFBSs significantly
over-represented in class (C1 and C3) relative to class
C4 (we determined 44 such cTFBSs), and (c) mapping
significantly over-represented cTFBSs determined in (b)
to promoters of genes in class C2. In (c), we requiredFigure 1 Defining the minimum number of cTFBSs required for the id
graphical representation of the proportion of genes that contain multiple c
defining the maximum difference between the known estrogen responsivethat at least four of the 44 cTFBSs map the promoters of
each gene in class C2. This threshold corresponds to the
maximum difference in the number of genes with these
cTFBSs in the positive set (class (C1 and C3)) as com-
pared to the background set (class C4) (Figure 1). All
class C2 genes that have such cTFBSs in their promoters
(we found 32 such genes) we considered as new candi-
date estrogen responsive ESCC genes since they have in
their promoters both: a/mapped EREs, and b/cTFBSs
characteristic of ESCC genes that are responsive to es-
trogen. This increases confidence that these 32 ESCC
genes are responsive to estrogen since due to the similar
regulatory potential with estrogen-responsive genes,
these genes have higher chance to express when
estrogen-responsive genes are expressing and addition-
ally they have ERE that potentially bind ERs.
TFBS matrices mapped to the promoters of 418 ESCC genes
The TRANSFAC mammalian matrix models of TFBSs
(Tranfac Professional v.11.4) were mapped to the pro-
moters of estrogen responsive genes in ESCC using
Match™ [30-32]. Of the 522 matrices mapped, 492
mapped to the promoters of the 418 ESCC genes at
165,787 positions, not considering strand (Additional
file 2).
cTFBSs significantly over-represented in class (C1 and C3) as
opposed to class C4
We developed a methodology to identify the cTFBSs sig-
nificantly over-represented in the known estrogen re-
sponsive gene set (class (C1 and C3)) relative to the
background set (class C4) (see methodology). Each TFBS
was ranked using a method that ensures that the topentification of estrogen responsive ESCC genes. This figure is a
TFBSs mapped to their promoters. The graph depicts the threshold
genes (C1 and C3) relative to the background set (C4).
Table 2 The cTBFSs mapped to the promoters of the 418 genes differentially expressed in ESCC
ERE Category C1+C3 C1 C2 C3 C4
Number of
Genes
202 56 72 146 144
Genes % Genes % Genes % Genes % Genes %
cTFBS38 V$AREB6_01|V$YY1_01|V$CETS1P54_01|V$E2A_Q6 17 8.42% 8 14.29% 9 12.50% 9 6.16% 0 0.00%
cTFBS39 V$AREB6_01|V$FREAC4_01|V$EBOX_Q6_01|V$E2A_Q6 16 7.92% 11 19.64% 7 9.72% 5 3.42% 0 0.00%
cTFBS44 V$TAXCREB_02|V$AREB6_01|V$CETS1P54_01|V$EBOX_Q6_01|V$CREB_Q3|V$E2A_Q6 16 7.92% 9 16.07% 7 9.72% 7 4.79% 0 0.00%
cTFBS43 V$TAXCREB_02|V$AREB6_01|V$EBOX_Q6_01|V$CREB_Q3|V$E2A_Q6 19 9.41% 9 16.07% 11 15.28% 10 6.85% 0 0.00%
cTFBS17 V$TAXCREB_02|V$FREAC4_01|V$E2A_Q6 18 8.91% 10 17.86% 8 11.11% 8 5.48% 0 0.00%
cTFBS34 V$TAXCREB_02|V$AREB6_01|V$CREB_Q3|V$E2A_Q6 22 10.89% 10 17.86% 14 19.44% 12 8.22% 0 0.00%
cTFBS33 V$TAXCREB_02|V$AREB6_01|V$ELK1_01|V$CREB_Q3 18 8.91% 8 14.29% 8 11.11% 10 6.85% 0 0.00%
cTFBS41 V$TAXCREB_02|V$AREB6_01|V$CETS1P54_01|V$CREB_Q3|V$E2A_Q6 17 8.42% 9 16.07% 9 12.50% 8 5.48% 0 0.00%
cTFBS32 V$TAXCREB_02|V$ELK1_01|V$EBOX_Q6_01|V$CREB_Q3 19 9.41% 10 17.86% 8 11.11% 9 6.16% 1 0.69%
cTFBS23 V$AREB6_01|V$ELK1_01|V$CREB_Q3 19 9.41% 8 14.29% 8 11.11% 11 7.53% 1 0.69%
cTFBS35 V$TAXCREB_02|V$AREB6_01|V$EBOX_Q6_01|V$CREB_Q3 21 10.40% 11 19.64% 11 15.28% 10 6.85% 1 0.69%
cTFBS26 V$AREB6_01|V$FREAC4_01|V$E2A_Q6 19 9.41% 13 23.21% 7 9.72% 6 4.11% 1 0.69%
cTFBS37 V$AREB6_01|V$CETS1P54_01|V$CREB_Q3|V$E2A_Q6 19 9.41% 10 17.86% 9 12.50% 9 6.16% 1 0.69%
cTFBS16 V$TAXCREB_02|V$FREAC4_01|V$CETS1P54_01 20 9.90% 14 25.00% 10 13.89% 6 4.11% 1 0.69%
cTFBS36 V$TAXCREB_02|V$EBOX_Q6_01|V$CREB_Q3|V$E2A_Q6 24 11.88% 12 21.43% 12 16.67% 12 8.22% 1 0.69%
cTFBS42 V$TAXCREB_02|V$AREB6_01|V$CETS1P54_01|V$EBOX_Q6_01|V$E2A_Q6 21 10.40% 12 21.43% 12 16.67% 9 6.16% 1 0.69%
cTFBS22 V$FREAC4_01|V$CETS1P54_01|V$EBOX_Q6_01 18 8.91% 13 23.21% 10 13.89% 5 3.42% 1 0.69%
cTFBS40 V$AREB6_01|V$EBOX_Q6_01|V$CREB_Q3|V$E2A_Q6 21 10.40% 10 17.86% 11 15.28% 11 7.53% 1 0.69%
cTFBS21 V$FREAC4_01|V$CETS1P54_01|V$E2A_Q6 18 8.91% 12 21.43% 7 9.72% 6 4.11% 1 0.69%
cTFBS28 V$AREB6_01|V$EBOX_Q6_01|V$CREB_Q3 23 11.39% 12 21.43% 11 15.28% 11 7.53% 2 1.39%
cTFBS20 V$TAXCREB_02|V$EBOX_Q6_01|V$CREB_Q3 27 13.37% 14 25.00% 13 18.06% 13 8.90% 2 1.39%
cTFBS31 V$TAXCREB_02|V$ELK1_01|V$CETS1P54_01|V$EBOX_Q6_01 23 11.39% 14 25.00% 16 22.22% 9 6.16% 2 1.39%
cTFBS27 V$AREB6_01|V$CREB_Q3|V$E2A_Q6 24 11.88% 11 19.64% 14 19.44% 13 8.90% 2 1.39%
cTFBS8 V$FREAC4_01|V$EBOX_Q6_01 22 10.89% 15 26.79% 13 18.06% 7 4.79% 3 2.08%
cTFBS18 V$TAXCREB_02|V$AREB6_01|V$CREB_Q3 27 13.37% 12 21.43% 17 23.61% 15 10.27% 3 2.08%
cTFBS24 V$AREB6_01|V$CETS1P54_01|V$CREB_Q3 24 11.88% 11 19.64% 9 12.50% 13 8.90% 3 2.08%
cTFBS13 V$TAXCREB_02|V$ELK1_01|V$CREB_Q3 28 13.86% 12 21.43% 11 15.28% 16 10.96% 3 2.08%
cTFBS9 V$AREB6_01|V$FREAC4_01 26 12.87% 15 26.79% 11 15.28% 11 7.53% 4 2.78%
cTFBS19 V$TAXCREB_02|V$CREB_Q3|V$E2A_Q6 30 14.85% 14 25.00% 15 20.83% 16 10.96% 4 2.78%
cTFBS7 V$FREAC4_01|V$E2A_Q6 25 12.38% 14 25.00% 9 12.50% 11 7.53% 4 2.78%
cTFBS30 V$EBOX_Q6_01|V$CREB_Q3|V$E2A_Q6 27 13.37% 13 23.21% 13 18.06% 14 9.59% 4 2.78%
cTFBS1 V$ELK1_01|V$CREB_Q3 32 15.84% 12 21.43% 11 15.28% 20 13.70% 5 3.47%



















Table 2 The cTBFSs mapped to the promoters of the 418 genes differentially expressed in ESCC (Continued)
cTFBS15 V$TAXCREB_02|V$CETS1P54_01|V$EBOX_Q6_01 34 16.83% 18 32.14% 21 29.17% 16 10.96% 5 3.47%
cTFBS25 V$AREB6_01|V$CETS1P54_01|V$E2A_Q6 30 14.85% 16 28.57% 16 22.22% 14 9.59% 5 3.47%
cTFBS10 V$AREB6_01|V$CREB_Q3 31 15.35% 13 23.21% 17 23.61% 18 12.33% 6 4.17%
cTFBS14 V$TAXCREB_02|V$CETS1P54_01|V$E2A_Q6 33 16.34% 15 26.79% 19 26.39% 18 12.33% 6 4.17%
cTFBS12 V$EBOX_Q6_01|V$CREB_Q3 32 15.84% 16 28.57% 15 20.83% 16 10.96% 7 4.86%
cTFBS29 V$AREB6_01|V$EBOX_Q6_01|V$E2A_Q6 38 18.81% 16 28.57% 21 29.17% 22 15.07% 8 5.56%
cTFBS2 V$ELK1_01|V$EBOX_Q6_01 36 17.82% 17 30.36% 18 25.00% 19 13.01% 9 6.25%
cTFBS3 V$CETS1P54_01|V$CREB_Q3 38 18.81% 15 26.79% 14 19.44% 23 15.75% 10 6.94%
cTFBS4 V$CETS1P54_01|V$EBOX_Q6_01 41 20.30% 21 37.50% 24 33.33% 20 13.70% 11 7.64%
cTFBS5 V$TAXCREB_02|V$CREB_Q3 43 21.29% 18 32.14% 23 31.94% 25 17.12% 12 8.33%
cTFBS11 V$AREB6_01|V$E2A_Q6 50 24.75% 23 41.07% 25 34.72% 27 18.49% 16 11.11%
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more likely to be co-localized within the promoters. In
order to reduce the search space for the potentially sig-
nificant co-localized TFBSs, a heuristic approach was ap-
plied where the 10 TFBSs with the lowest p-value (see
Materials and Methods) were selected for subsequent
analysis. Every possible combination of cTFBSs that
includes some of the 10 TFBS were determined. The sig-
nificant cTFBSs with a p-value (corrected for multiplicity
testing) < 0.05 were selected.
We identified 44 significant cTFBSs consisting of 12
doublet cTFBS, 18 triplet cTFBS, 10 4-element cTFBS, 3
5-element cTFBS and 1 6-element cTFBS (Table 2). The
10 TFBSs that make these cTFBSs are determined by the
following TRANSFAC identifiers V$ELK1_01, V
$CETS1P54_01, V$YY1_01, V$GATA3_01, V$TAX-
CREB_02, V$FREAC4_01, V$AREB6_01, V$CREB_Q3, V
$E2A_Q6 and V$EBOX_Q6_01. Of the 44 cTFBSs, eight
combinations were completely absent in the background
set (class C4). The most significant cTFBSs (V$TAX-
CREB_02, V$AREB6_01, V$CREB_Q3 and V$E2A_Q6)
was not present in class C4, but mapped 10 times to the
promoters of genes in class C1 and 12 times to the pro-
moters of genes in class C3.
44 cTFBSs used to increase confidence in a subset of the
new candidate estrogen responsive genes in class C2
We mapped the 44 significant cTFBSs to the promoters
of the genes in class C1, C2, C3 and C4 thereby generat-
ing 574, 567, 561 and 153 predictions of cTFBSs, respect-
ively. This result for the mapping of cTFBSs to the
promoters of all categories indicates that multiple cTFBSs
are present in the promoters of genes. Moreover, these
multiple cTFBSs are more dominant in genes from class
(C1 and C3) known to be responsive to estrogen, as well
as genes with ERE predictions in their promoters (class
C2). Consequently, we applied a threshold that each gene
promoter must contain at least four of the significant
cTFBSs, as this threshold defines the maximum difference
in the number of genes that contain such cTFBSs between
the known estrogen responsive gene set (class (C1 and
C3)) relative to the background set (class C4) (refer to
Figure 1). It was determined that at least four of the sig-
nificant cTFBSs were present in 51.8% (29/56) of the
genes in class C1 (class C1A), 44.4% (32/72) of the genes
in class C2 (class C2A), 23.3% (34/146) of the genes in
class C3 (class C3A) and 7.6% (11/144) of the genes in
class C4 (class C4A) (Additional file 3). An overview of
the regulatory effects of the cTFBSs on the 32 genes in
class C2A is shown in Figure 2. This figure illustrates each
association in class C2A, in the form of a color dot in a
heat map format using TMEV [33,34]. The heat map
clearly depicts gene clusters based on the cTFBSs com-
mon to the promoters of multiple genes in class C2A.Moreover, a review of the recently published scientific
literature reveals that 47% (15/32) of the C2A genes have
now been shown experimentally to be estrogen respon-
sive. These 15 genes include MUC5B [35], MMP2 [36],
LOXL2 [37], ACTN4 [38], DNMT1 [39], GPR56 [40],
MUC4 [40], WNT7B [41], BMP6 [42], GPX3 [43],
CDC25B [44], NFκB1 [45], PRDM2 [46], MDM2 [47]
and TIMP2 [48].
Discussion
In this study, we propose a methodology aimed at pro-
viding an insight into the underlying transcription
regulatory potential related to genes’ response to estro-
gen in ESCC. In this systems biology study, we com-
bined information obtained from several databases,
genomic sequences of promoters of relevant genes,
and analysis of transcription regulation potential of
these genes to infer if the genes are estrogen respon-
sive. Two computational components are used to sug-
gest ESCC genes responsive to estrogen: 1) the ERE
prediction (made by Dragon ERE Finder version 6.0),
and 2) predicted cTFBSs that characterize the promo-
ters of known estrogen responsive ESCC genes (these
were obtained based on methodology we developed in
this study). These cTFBSs were mapped to the promo-
ters of ESCC genes not being known to be responsive
to estrogen, but having ERE predictions in their pro-
moters. In this way we increased the confidence that
the ESCC genes with ERE predictions are responsive
to estrogen since they, in addition to EREs, also con-
tain cTFBSs characteristic of estrogen responsive ESCC
genes.
ESCC genes predicted to be responsive to estrogen
Carroll et al. has reported that ER binds selectively to a
limited number of sites, majority of which are distant
from the transcriptional start sites of regulated genes
and that direct ER binding requires the presence of fork-
head factor (foxa1) binding in close proximity [49].
However, several computational approaches has been
undertaken to identify target genes based on the pres-
ence of EREs in the proximal promoter regions [25,50].
Bourdeau et al. in particular screened for EREs that were
conserved in the human and mouse genome and identi-
fied 660 gene proximal EREs of which several were vali-
dated as genuine ER interaction sites [50]. This analysis
has also been restricted to the proximal promoter region
due to computational limitations and regulatory TFs
binding closer to the transcription start site. EREs were
mapped to the promoters of 418 ESCC genes using the
Dragon ERE Finder version 6.0 (http://apps.sanbi.ac.za/
ere/index.php). Bajic et al. (2003) have demonstrated
that this ERE locator predicts known ERE and estrogen
responsive genes at a sensitivity of 0.83. We further
Figure 2 An overview of the cTFBSs and their regulatory effects on the ESCC genes. The figure represents a heat map of cTFBSs that are
significantly over-represented in the promoters of the known estrogen response genes in ESCC (columns) mapped to the promoters of the new
candidate estrogen response genes in C2A (rows). The red shading depicts the association between the gene promoter and the cTFBSs, while
white depicts no association.
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sponsive to estrogen using the KBERG [26] and ERTar-
getDB [27] databases. Of the 128 predicted estrogen
responsive genes, 43.75% (56/128) are known to be es-
trogen responsive, while 56.25% (72/128) were novel pu-
tative estrogen responsive genes. These 72 genes lay the
foundation for increasing insights into the molecular
events triggered by estrogen via an ERE dependant mode
of regulation in ESCC. EREs did not map to 290 ESCC
genes of which 50.34% (146/290) are known to be re-
sponsive to estrogen. The promoters of these 146 gene
did not contain an ERE motif, but the genes are known
to be responsive to estrogen. The response to estrogen
of these genes may be through the interactions of ERs
with other transcription factors forming complexes that
do not require the presence of EREs [51]. It is alsopossible that the ERE models are not sufficiently good to
predict EREs in these promoter regions. Our analysis
generated four gene categories (Table 1): class C1 (56
ESCC genes), class C2 (72 ESCC genes), class C3 (146
ESCC genes), and class C4 (144 ESCC genes). We found
that the four gene categories had a different number of
enriched pathways using Kyoto Encyclopedia of Genes
and Genomes (KEGG) (see Methodology and Additional
file 4). However, in each category the more general
KEGG pathway “Pathways in cancer” (hsa05200)
enriched with genes forming the gene sets. Other more
specialized and equally important pathways show enrich-
ment with genes forming certain categories. Category 1
genes are highly enriched in the pathways such as “Tran-
scriptional misregulation in cancer” (hsa05202), “Small
cell lung cancer” (hsa05222), “Melanoma” (hsa05218).
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e.g. “p53 signaling pathway” (hsa04115), “Bladder cancer”
(hsa05219), “Small cell lung cancer” (hsa05222). Category 3
genes are highly enriched for many pathways, e.g. “Prostate
cancer” (hsa05215),“Colorectal cancer” (hsa05210), “Small
cell lung cancer” (hsa05222), “Chronic myeloid leukemia”
(hsa05220), “Endometrial cancer” (hsa05213), etc. Category
4 genes is additionally highly enriched in the “Bladder can-
cer” (hsa05219) pathway. These categories were used to
identify the cTFBSs that characterize the promoters of the
202 (56 + 146) ESCC gene (from class (C1 and C3))
known to be responsive to estrogen.
The cTFBSs that characterize the promoters of ESCC
genes known to be responsive to estrogen
Since gene expression is driven by the cohesive action
of multiple TFs binding to specific TFBSs, common
cTFBSs may define co-regulated genes [14,52]. We iden-
tified cTFBSs significantly over-represented in the pro-
moters of genes known to be responsive to estrogen
(class (C1 and C3)) as compared to the background set
(class C4). When comparing the 202 (56 +146) known
estrogen responsive genes (class (C1 and C3)) to the
background set (class C4), we selected the 10 TFBSs
(see Material and Methods) to be used in subsequent
analysis. Every possible combination of cTFBSs made
of these 10 TFBSs were determined. The significant
cTFBSs with a p-value (corrected for multiplicity testing)
< 0.05 were selected.
44 significant cTFBSs were identified, eight of which
were not present in the background set (class C4). The
most significant cTFBS comprised of the following
TRANSFAC identifiers: V$TAXCREB_02, V$AREB6_01,
V$CREB_Q3 and V$E2A_Q6. The above mentioned
cTFBS was not present in class C4, but mapped to the
promoters of 14.29% of genes in class C1, 6.16% of genes
in class C3, and 12.50% of genes in class C2 (Table 2).
V$AREB6_01 is known to bind AREB6 (also known as
ZEB1) [53]; V$TAXCREB_02 binds CREB, deltaCREB
and Tax/CREB complex [54,55]; V$CREB_Q3 possibly
binds CREB1, CREMalpha, deltaCREB, ATF-1, ATF-2,
ATF-3, ATF-4, ATF-a, and ATF-2-xbb4; and V$E2A_Q6
possibly binds E2A, TCF4, TCF12, TFF3, ASCL1, MYF3,
MYF4, MYF5, and MYF6. None of the above mentioned
TFs has been linked to estrogen, but play a role in the
progression of cancer [56-59]. Further details of these
TFBSs and their associated TFs can be viewed in
Additional file 5.
Even though we have identified cTFBSs that
characterize the promoter regions of the known estrogen
responsive genes in ESCC, it is unclear whether the
TFs that bind the TFBSs function as transcriptional
activators or transcriptional repressors in the estrogen
responsive ESCC genes [60-62]. Nonetheless, thesesignificant cTFBSs are over-represented in the promo-
ters of known estrogen responsive genes and thus can
be used to identify genes that are likely co-regulated
with genes responsive to estrogen.
Identification of candidate estrogen responsive ESCC
genes with EREs and cTFBSs mapped to the promoters
The 44 significantly over-represented cTFBSs were used
to increase confidence in a subset of the new candidate
estrogen responsive genes in class C2. It was determined
that at least four of the significant cTFBSs were present
in 51.8% (29/56) of the genes in class C1 (class C1A),
44.4% (32/72) of the genes in class C2 (class C2A),
23.3% (34/146) of the genes in class C3 (class C3A) and
7.6% (11/144) of the genes in class C4 (class C4A)
(Additional file 3).
The 44 cTFBSs were determined based on class (C1
and C3), but the findings show that the genes with the
cTFBSs are concentrated in class C1 (genes both pre-
dicted and confirmed to be responsive to estrogen),
since class C1 has 28.5% more genes with a cTFBSs in
the promoter sequence as compared to class C3. This
result indicates that class C1A gene promoters with
EREs also contain distinctive cTFBSs that may define
multiple co-regulated genes responsive to estrogen.
These co-regulated genes may define estrogen respon-
sive genes that function in an ERE-dependent manner.
Thus, the 32 genes with putative EREs in class C2A that
have at least four of the cTFBSs may be an additional
fraction of these co-regulated genes. These results in-
crease confidence in the new candidate estrogen respon-
sive genes in class C2A since they contain both EREs
and cTFBSs characteristic of ESCC genes that are re-
sponsive to estrogen.
We found 38 TFs that interact with ER via 137 signifi-
cant (p-value threshold of <0.05) binding sites using Bio-
GRID [63] and the TRANSFAC [31] databases
(Additional file 6), of which at least one binding site is in
close proximity to the ERE of the 32 genes identified as
estrogen responsive. We additionally found 18 (ESR1,
ETS1, FOS, GATA4, HIC1, HIF1A, FOXA1, IRF2, AR,
MYC, NFKB1, RARA, RELA, STAT3, NR2F2, TP53,
WT1, FOSL1) TFs to be self-regulating. Interestingly,
one group [49] has reported that their unbiased se-
quence interrogation of the genuine chromatin binding
sites suggests that direct ER binding requires the pres-
ence of foxa1 binding in close proximity, as knockdown
of FoxA1 expression blocked the association of ER with
the chromatin and estrogen induced gene expression.
We do not know if this estrogenic response requirement
is restricted to breast cancer cells, but 62.5% of the 32
genes we have identified as estrogen responsive has the
ERE in close proximity to the FoxA1 binding site. Fur-
ther, we provide an overview of the potentially co-
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(Figure 2). Figure 2 clusters class C2A genes based on
the presence of common cTFBSs mapped to the gene
promoters. Multiple clusters of genes in the heat map
show that different groups of genes have different spe-
cific combinations of cTFBSs, making them more likely
to be co-regulated. AKAP13 (Gene ID: 11214), LOXL2
(Gene ID: 4017), and TIMP2 (Gene ID: 7077) cluster to-
gether and contain the highest number of combinations
that are common to their promoters. We further ranked
the 32 genes based on the number of cTFBSs present in
each promoter (Additional file 7). AKAP13, LOXL2,
TIMP2, CDC25B, MUC2, CRLF1, VIM, MMP2 and
MUC5B are identified as the top nine ranked genes.
A further literature survey disclosed that AKAP13
belongs to the Dbl family of proto-oncogenes that func-
tion as a Rho family guanine nucleotide exchange factor.
It is known to bind and influence the activity of gluco-
corticoid receptors (GRs) and ERs [64,65]. It has been
experimentally demonstrated that AKAP13 interacts
with the ligand activated ER to form a tertiary complex
with either RhoA or rho related GTPase CDC42
(Figure 3). It has been demonstrated that these com-
plexes bind to ERE sites thereby driving genes expres-
sion induced by estrogen [66]. Interestingly, RhoA is
also known to be up-regulated in ESCC [67]. Moreover,Figure 3 An illustration of the ERs transcriptional activation process.
→ ERE” dependent transcriptional activation process that requires the cand
co-factors.the p38 MAPK inhibitor SB202190 abrogates ERβ activ-
ity by AKAP13 indicating that AKAP13 activates ERβ
via the p38 MAPK pathway [66]. Pathway analysis using
DAVID [68] indicates that four of our putative estrogen
response genes (FGFR4, RELA, NFκβ and CDC25B) are
involved in the MAPK signaling pathway. CDC25B
belongs to the CDC25 family of phosphatases that acti-
vates cyclin dependent kinases by removal of inhibitory
phosphates. This gene is also known to bind and influ-
ence the activity of nuclear receptors such as progester-
one receptor (PR) and ER. It has been experimentally
demonstrated that CDC25B interacts with the ligand
activated ER in a hormone-dependent ER transactivation
manner. Also, the p300/CBP-associated factor and CREB
binding protein were shown to interact and synergize
with CDC25B and further enhance its co-activation ac-
tivity [69]. These findings link AKAP13 and CDC25B,
two of the top 10 ranked putative estrogen response
genes, to estrogen activity and highlight their function-
ing as co-factors in the ERs transcriptional activity.
Because these genes are putative estrogen responsive
genes, this finding may be indicative of a cascading
event that may be an important step in regulating
hormone-dependent ER transactivation.
Recent publications show that MUC5B [35], MMP2
[36], LOXL2 [37], ACTN4 [38], DNMT1 [39], GPR56This figure is a pictorial representation of the known “estrogen→ ER
idate estrogen responsive gene products, AKAP13 and CDC25B, as
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CDC25B [44], NFκB1 [45], PRDM2 [46], MDM2 [47]
and TIMP2 [48] are responsive to estrogen. These find-
ings further increase confidence that the 32 new candi-
date estrogen responsive ESCC genes may indeed be
estrogen responsive.
Conclusion
Our study proposes a methodology that provides
insight into the regulatory potential of estrogen respon-
sive genes and identifies 32 new candidate estrogen re-
sponsive genes using ESCC as the framework. AKAP13,
LOXL2, TIMP2, CDC25B, MUC2, CRLF1, VIM, MMP2
and MUC5B were identified as the top nine ranked
genes, of which AKAP13 [64,66] and CDC25B [69]
have independently been identified in other studies as
essential components of ER complexes that are
required to drive estrogen induced gene expression.
Moreover, estrogen responsiveness of 47% (15 out of
32) of genes predicted by our method is supported by
experimental findings in recent publications. These
insights into the transcription regulation potential asso-
ciated with estrogen response provide information of
potential interest to those with interest in studying es-
trogen effects in ESCC and in design estrogen-based
EC therapies. This study is the first to use a cancer dis-
ease model as the framework to identify hormone re-
sponsive genes. Although we used ESCC and estrogen
for this purpose, the methodology, however, can be
extended analogously to use other diseases as the
model and other hormones.
Methods
Extracting promoter regions of genes differentially
expressed in ESCC
A total of 418 genes were extracted from the Dragon
Database of Genes Implicated in Esophageal Cancer
(DDEC) [28]. The promoters (1200 bp upstream and
200 bp downstream from the transcription start site,
TSS) of all 418 ESCC genes under study were extracted
from the Fantom3 CAGE tag data that correspond to
1645 transcription start sites (TSSs) that each have at
least five tags in the tag cluster and a minimum of three
tags corresponding to the representative tag [29].
Annotating and classifying ESCC genes according to
predicted and validated estrogen response
Dragon ERE Finder version 6.0 (http://apps.sanbi.ac.za/
ere/index.php) was used to predict EREs in the promoter
regions of ESCC genes. A sensitivity of 0.83 was used as
recommended in [25]. Based on the presence of pre-
dicted EREs the 418 ESCC genes were divided into two
groups: 1) genes whose promoters contain predicted
EREs, and 2) genes lacking predicted EREs. These twogene groups were further divided into those known to
be experimentally confirmed as estrogen responsive and
those that are not, by cross-checking the all ESCC genes
against the estrogen responsive genes in the KBERG [26]
and ERtargetDB [26] databases. The KBERG database
contained 1516 experimentally confirmed estrogen-
responsive genes. The ERTargetDB, database contained:
(a) 40 genes with 48 experimentally verified ERE direct
binding sites and 11 experimentally verified ERE tethering
sites; (b) 42 genes identified via ChIP-on-chip assay for
estrogen binding and (c) 355 genes from gene expres-
sion microarrays, all of which were included in this
study. However, this study excludes the 2659 computa-
tionally predicted estrogen responsive genes included
the ERTargetDB, database.
Thus we classified the 418 ESCC genes into the fol-
lowing four categories:
– C1/ESCC genes with predicted EREs in their
promoters and known as estrogen responsive,
– C2/ESCC genes with predicted EREs in their
promoters but not known as estrogen responsive,
– C3/ESCC genes having no predicted EREs in their
promoters, but known as estrogen responsive,
– C4/ESCC genes having no predicted EREs in their
promoters and not known as estrogen responsive.
We used these categories to develop a methodology
for the identification of sets of co-localized TFBSs
(cTFBSs) that characterize the promoters of the known
estrogen responsive gene set (class C1 and C3) as
opposed to the background set (class C4).Gene-set pathway enrichment analysis
Gene enrichment in Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways was calculated using the
Fisher’s exact test based the hypergeometric distribution
[70] with all genes that are associated to at least one
KEGG pathway. All other genes were discarded for the
analysis. The set of genes was compared to the set of all
human genes that have at least one KEGG pathway asso-
ciated. Finally all p-values were adjusted using the
method by Benjamini and Hochberg to control the false
discovery rate [71] and only pathways retained were the
adjusted p-value is below 0.01. In total 253 KEGG path-
ways were under consideration.Identification of cTFBSs
TRANSFAC mammalian matrix profiles of TFBSs were
mapped to the promoters of all 418 ESCC genes under
study by using Match™ [30-32] with minFP profiles. We
developed the following 3-step methodology to identify
the cTFBSs significantly over-represented in the known
Essack et al. BMC Systems Biology 2012, 6:135 Page 11 of 13
http://www.biomedcentral.com/1752-0509/6/135estrogen responsive genes (class C1 and C3) as opposed
to the background set (class C4):
1. Given the full set of 522 TRANSFAC mammalian
matrices, we calculated the p-value for any given
matrix pair MiMj being present in greater
proportions in class (C1 and C3) promoters as
opposed to class C4. We did not take strand into
account. The p-values were calculated using the one-
sided Fisher’s exact test. In the case where Mi = Mj,
we corrected the p-values for multiple testing by a
factor of 522 (Bonferroni); when Mi ≠ Mj, we
corrected by a factor of 5222-522/2.
2. Having calculated the corrected p-value for each




S22 p(MiMj). Roughly, one would expect to
have more abundant Mi in class (C1 and C3)
promoters as opposed to class C4 promoters when
the smaller the score Si. Additionally, groups of
matrices with similarly low scores tend to co-localize
more often in the promoters of class (C1 and C3)
than in the promoters of class C4 genes.
3. We selected 10 matrices with the lowest p-values,
calculated as described above. Using these 10
matrices we tested for the disproportionate presence
of all combinations consisting of 2 to 10 of these
matrices (cTFBSs) between the class (C1 and C3)
and class C4 gene promoter sets. A Bonferroni
correction factor of (k
n) was applied, where n = 10
and k equates to the number of matrices under
consideration per combination. Significance was
determined at the corrected p-value ≤ 0.05.
In the above manner a total of 44 cTFBSs were
found to be significantly over-represented in the
promoters of class (C1 and C3).Annotation of class C2 genes implicated in ESCC as
estrogen responsive
We found that many of the 44 over-represented cTFBSs
were indeed present in class C2. However, we applied a
threshold that each gene must map at least four of the
significant cTFBSs, as this threshold defines the max-
imum difference between the known estrogen responsive
gene set (class (C1 and C3)) relative to the background
set (class C4). Thus, by using four cTFBSs as a threshold,
we putatively annotated 44.4% of the genes in as being
estrogen responsive. These annotations are made viewable
in the form of a heat-map using TMEV [33,34]. The
heat map is based on hierarchical clustering with average
linkage and Euclidian distance. The shade of red depicts
an association between the gene and the cTFBSs, while no
shade indicates that the cTFBS could not be mapped onto
the gene’s promoter.Additional files
Additional file 1: ESCC genes categorized based on ERE predictions
and experimental evidence of estrogen responsiveness. Appendix I.
xls contains all the 418 ESCC genes tabulated based on ERE predictions
and experimental evidence of estrogen responsiveness.
Additional file 2: TFBS matrices mapped to the promoters of the
ESCC genes. Appendix II.xls contains all the TFBS matrices mapped to
the promoters of the ESCC genes.
Additional file 3: Multiple cTFBSs mapped to the promoters of the
ESCC genes. Appendix III.xls contains the number of multiple cTFBS
matrices mapped to the promoters of the ESCC genes in categories C1,
C2, C3 nad C4.
Additional file 4: Pathways enriched in the Four ESCC gene
categories. Appendix IV.xls contains details of the enriched KEGG
pathways in the four gene categories.
Additional file 5: The most significant cTFBS. Appendix V.xls contains
details of the most significant combination of cTFBSs comprising V
$TAXCREB_02, V$AREB6_01, V$CREB_Q3 and V$E2A_Q6.
Additional file 6: The significant TFBSs and their associated TFs.
Appendix VI.xls contains details of the 137 significant TFBSs and the TFs
that bind them.
Additional file 7: Ranked list of putative estrogen responsive ESCC
genes. Appendix VII.xls contains a ranked list of putative estrogen
response ESCC genes based on the number of cTFBSs mapped the
promoter.
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